Protection of normal cells and tissues during radio- and chemosensitization of tumors by 2-deoxy-D-glucose
- PMID: 20009291
- DOI: 10.4103/0973-1482.55138
Protection of normal cells and tissues during radio- and chemosensitization of tumors by 2-deoxy-D-glucose
Abstract
Normal tissue toxicity is one of the major limiting factors in cancer therapy. Damage to normal tissues and critical organs restricts the use of higher therapeutic doses thereby compromising the efficacy. The glucose analog 2-deoxy-D-glucose (2-DG), an inhibitor of glycolytic ATP production has been shown to enhance radiation- and chemotherapeutic drug-induced damage in a number of cancer cells under in vitro and in vivo conditions while sparing or protecting normal cells. This review summarizes current understanding on the protection of normal cells and tissues against radiation- and chemotherapeutic drug-induced damage by 2-DG that makes this glucose analog an ideal adjuvant in cancer therapy.
Similar articles
-
Cytotoxicity, radiosensitization, and chemosensitization of tumor cells by 2-deoxy-D-glucose in vitro.J Cancer Res Ther. 2009 Sep;5 Suppl 1:S27-31. doi: 10.4103/0973-1482.55137. J Cancer Res Ther. 2009. PMID: 20009290 Review.
-
Modification of 2-deoxy-D-glucose on radiation-and chemotherapeutic drug-induced chromosomal aberrations.J Cancer Res Ther. 2009 Sep;5 Suppl 1:S48-52. doi: 10.4103/0973-1482.55142. J Cancer Res Ther. 2009. PMID: 20009295
-
Glycolytic inhibitor, 2-deoxy-D-glucose, does not enhance radiation-induced apoptosis in mouse thymocytes and splenocytes in vitro.Indian J Exp Biol. 2005 Aug;43(8):686-92. Indian J Exp Biol. 2005. PMID: 16121709
-
Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors.J Cancer Res Ther. 2009 Sep;5 Suppl 1:S16-20. doi: 10.4103/0973-1482.55135. J Cancer Res Ther. 2009. PMID: 20009287 Review.
-
Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects.J Cancer Res Ther. 2009 Sep;5 Suppl 1:S21-6. doi: 10.4103/0973-1482.55136. J Cancer Res Ther. 2009. PMID: 20009289 Review.
Cited by
-
Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics.Heliyon. 2022 Aug 27;8(8):e10450. doi: 10.1016/j.heliyon.2022.e10450. eCollection 2022 Aug. Heliyon. 2022. PMID: 36082331 Free PMC article. Review.
-
Differential killing and radio-modifying effects of iodoacetate in mammalian normal and cancer cells.Radiat Environ Biophys. 2017 Aug;56(3):227-239. doi: 10.1007/s00411-017-0699-0. Epub 2017 Jun 13. Radiat Environ Biophys. 2017. PMID: 28612110
-
2-Deoxy-d-Glucose Can Complement Doxorubicin and Sorafenib to Suppress the Growth of Papillary Thyroid Carcinoma Cells.PLoS One. 2015 Jul 2;10(7):e0130959. doi: 10.1371/journal.pone.0130959. eCollection 2015. PLoS One. 2015. PMID: 26134286 Free PMC article.
-
Defective glycolysis and the use of 2-deoxy-D-glucose in polycystic kidney disease: from animal models to humans.J Nephrol. 2017 Aug;30(4):511-519. doi: 10.1007/s40620-017-0395-9. Epub 2017 Apr 7. J Nephrol. 2017. PMID: 28390001 Review.
-
Metabolic Rewiring in Cancer: Small Molecule Inhibitors in Colorectal Cancer Therapy.Molecules. 2024 May 2;29(9):2110. doi: 10.3390/molecules29092110. Molecules. 2024. PMID: 38731601 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources